One million DBS samples received, analyzed and reported
As of December 16, 2021 we have reached an important and noteworthy milestone. One million dried blood spot (DBS) samples have been sent from customers all around the world for analysis of different biomarkers. We currently receive 350 000 DBS samples annually with typical 25 % increase per year, and the rate is increasing from year to year as new customers and new assays are made available.
Test for covid-19 antibodies on dried blood spots (DBS)
One newly discovered mutant of the SARS-CoV-2 virus is omicron. The scientific community is working intensely to clarify if the available vaccines protect against omicron, and if the rapid test antigen for the spike 1 protein recognizes the virus and with what sensitivity. Antibodies produced due to omicron infection may also be different from other mutations and undetectable with IgG assays based on the original spike 1 protein.
Pharma & Nutra Services
Our laboratories, equipped with the most modern instrumentation including UPLC, HPLC, LC-MS, LC-MS/MS, LC-TOF-HRMS, GC, GC-MS systems are operated by a well trained and highly motivated staff with an average of more than 10 years of practical experience. The pharmaceutical analytical section of the laboratory is GMP-inspected and under control of the relevant authorities.
Dried blood spot (DBS) services
The collection of whole blood samples on paper, known as dried blood spot (DBS), dates back to the early 1960s in new-born infant screening for inherited metabolic disorders. DBS offers several advantages compared to conventional blood collection. It is less invasive, easier to transport and store, with reduced risk of infection from various pathogens, and it only requires a few drops of blood.